



Mutation Analysis Program† Enrollment Form

The Johns Hopkins Genomics DNA Diagnostic Laboratory (JHGDDL)

†Funded by the Cystic Fibrosis Foundation

Genomics - DDL 1812 Ashland Ave Sample Intake, Room 245 Baltimore, MD 21205

Shipping address:

Johns Hopkins

Fax completed forms to 410-367-3266. For questions, call the JHGDDL at 410-614-2750.

All fields must be complete and legible. Provider and patient stamps or stickers are *not* valid. Information must be typed or handwritten.

*MAP Authorization #:	Date:	For JHGDDL Use Only
Indicate whether this is the patient's first enro visit the Program	ollment, or whether the patient is eligil n website for eligibility requirements.	ble for re-enrollment. Please
	ed Re-Enrollment, CFFMAP Genetic ID:	
Referrer Information		
Referring Physician:	NPI:	
Nurse/Genetic Counselor/Social Worker:	Email:	
CF Care Center Name:	CF	Care Center ID #:
Address:		
City:	State:	Zip:
Phone Number:	Results to be faxed to:	
Institutional/Reference Lab/Sendout Lab Fax # (if applicable)	le):	
Patient Information *Two or more of these identifiers n *Patient Name: Last	First	
*Date of Birth (mm/dd/yyyy): Se	ex assigned at birth: Gender	r identity:
Address:		
City:	State:	Zip:
*Sample Accession # or Patient's Medical Record (MRN) #	<i>‡</i> :	
<u>Clinical Information</u> Please attach a copy of the patie	ent's most recent clinic note.	
Lowest sweat chloride concentration(s): (m	ımol/L)	
Has the patient ever received DNA testing? No	Yes Were variant(s) identified by prev	vious DNA testing?
If yes, indicate which variant(s):		
<u>Transfusion/Transplant Information</u> Please contain	act the lab to coordinate submission of alt	ternate sample types.
Blood and saliva samples are not acceptable if the patient Received blood products <2 weeks before specimen co Received a bone marrow or allogenic stem cell transpla Active hematologic malignancy; cultured skin fibroblast	ollection. Exceptions are made for pRBC ant. Cultured skin fibroblasts are the only	
 Received blood products <2 weeks before specimen co Received a bone marrow or allogenic stem cell transpla 	ollection. Exceptions are made for pRBC ant. Cultured skin fibroblasts are the only	
 Received blood products <2 weeks before specimen of Received a bone marrow or allogenic stem cell transplated. Active hematologic malignancy; cultured skin fibroblast For Internal Use Only 	ollection. Exceptions are made for pRBC ant. Cultured skin fibroblasts are the only	y accepted specimen type in this case.
 Received blood products <2 weeks before specimen of Received a bone marrow or allogenic stem cell transplated. Active hematologic malignancy; cultured skin fibroblast For Internal Use Only 	ollection. Exceptions are made for pRBC ant. Cultured skin fibroblasts are the only ts are the recommended sample type.	y accepted specimen type in this case.

Sample Collection Please select the type of sample to be submitted for testing.			
To be completed by provider after approval. Do not collect sample without prior approval. Date blood sample collected:	Not suitable for patients under 5 years of age. Do not use non-CFFMAP collection kits. A CFFMAP saliva kit will be sent to patient on approval. Note: The lab is unable to ship to a PO Box. Please provide a residential address.	Previously Submitted Specimen For patients qualified for re-enrollment, the lab will determine whether there is sufficient DNA remaining for processing. If a new sample is required, the lab will contact the provider.	
Mutation Analysis Program Informed Consent			
Provider Consent: Read and Sign I certify that I am the referring provider for the patient identified above, and have assisted the patient in completing this form. I certify that the patient identified above has a confirmed or strongly suspected CF diagnosis. I also understand that the Mutation Analysis Program (MAP) is not intended to be used to diagnose patients with CF, but rather used to identify the patient's unknown genetic variants(s). I certify that I have discussed the purpose of this genetic testing with the patient and explained to the patient that the testing may take up to three months to complete.			
Signature of Provider (Required) Signature Date (Required)		nature Date (Required)	
Patient Consent: Read and Sign			
I understand that my physician is requesting the Johns Hopkins Genomics DNA Diagnostic Laboratory (JHGDDL) to perform the Mutation Analysis Protocol on me/my dependent, and that my physician may provide a limited amount of health information with the request. The purpose and accuracy of this testing have been reviewed by my health care provider and my questions about these issues have been answered. I understand that in most cases, a negative test result does not necessarily rule out a hereditary condition. Results of DNA testing should be considered with the results of other types of testing and clinical evaluation. Test results may disclose non- paternity or other genetic conditions. No clinical tests other than those authorized will be performed; however, any remaining sample may be used for quality control purposes or research after de-identification. My physician will receive a clinical report, but the laboratory cannot guarantee turn-around time or that a result will be obtained on any sample. Release to other parties requires written consent of the patient.			
I have read and agree to the Program Informed Consent section above.			
Patient Name (Printed)	Da	ate of Birth (MM/DD/YYYY)	
Signature of Patient/Parent/Guar	dian (Required) Si	gnature Date (Required)	
Parent/Guardian Name (Printed)	Re	elationship to patient	
I would describe my race/ethnicity as (Black, African American, or of Africation East Asian Middle Eastern, Southwest Asian, N Hispanic, Latino/Latina/Latinx Native American, Alaska Native, Fir	an descent Native Hawaiian, Pacific South Asian North African Southeast Asian White	Islander	